Clinical Trials | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Subscribe To Our Newsletter & Stay Updated
